{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:21:50Z","timestamp":1770888110119,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.beha.2019.101137","type":"journal-article","created":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T22:27:12Z","timestamp":1576362432000},"page":"101137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management"],"prefix":"10.1016","volume":"33","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2019.101137_bib1","first-page":"766","article-title":"Chronic myelomonocytic leukemia","volume":"4","author":"Storniolo","year":"1990","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2019.101137_bib2","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.101137_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11864-002-0011-6","article-title":"Chronic myelomonocytic leukemia","volume":"3","author":"Bennett","year":"2002","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.beha.2019.101137_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjh.12756","article-title":"Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review","volume":"165","author":"Patnaik","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.101137_bib5","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2019.222059","article-title":"Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions","volume":"104","author":"Valent","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2019.101137_bib6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/10428190009058500","article-title":"Clinical and biologic diversity of leukemias occurring in patients with mastocytosis","volume":"37","author":"Sperr","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2019.101137_bib7","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41375-018-0121-1","article-title":"A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone","volume":"32","author":"Patnaik","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2019.101137_bib8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11899-015-0271-4","article-title":"Chronic myelomonocytic leukemia: a genetic and clinical update","volume":"10","author":"McCullough","year":"2015","journal-title":"Curr Hematol Malignancy Rep"},{"key":"10.1016\/j.beha.2019.101137_bib9","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.101137_bib10","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Canc J"},{"key":"10.1016\/j.beha.2019.101137_bib11","series-title":"World health organization classification of tumours \u2013 pathology & genetics: tumours of the haematopoietic and lymphoid tissues:","first-page":"49","article-title":"Chronic myelomonocytic leukemia","author":"Vardiman","year":"2001"},{"key":"10.1016\/j.beha.2019.101137_bib12","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues:","first-page":"76","article-title":"Chronic myelomonocytic leukemia","author":"Orazi","year":"2008"},{"key":"10.1016\/j.beha.2019.101137_bib13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101137_bib14","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues:","first-page":"82","article-title":"Chronic myelomonocytic leukemia","author":"Orazi","year":"2017"},{"key":"10.1016\/j.beha.2019.101137_bib15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","article-title":"Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias","volume":"38","author":"Schuler","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2019.101137_bib16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.clml.2016.08.005","article-title":"Changes in the updated 2016: WHO classification of the myelodysplastic syndromes and related myeloid neoplasms","volume":"16","author":"Bennett","year":"2016","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.beha.2019.101137_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3343\/alm.2018.38.5.481","article-title":"The 2016 WHO versus 2008 WHO criteria for the diagnosis of chronic myelomonocytic leukemia","volume":"38","author":"Moon","year":"2018","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.beha.2019.101137_bib18","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues:","first-page":"68","article-title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1","author":"Bain","year":"2008"},{"key":"10.1016\/j.beha.2019.101137_bib19","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues:","first-page":"72","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2","author":"Bain","year":"2017"},{"key":"10.1016\/j.beha.2019.101137_bib20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/modpathol.2017.45","article-title":"Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia","volume":"30","author":"Geyer","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.beha.2019.101137_bib21","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101137_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2017.12.002","article-title":"Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML","volume":"65","author":"Schuler","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2019.101137_bib23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.leukres.2006.11.009","article-title":"Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference","volume":"31","author":"Valent","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2019.101137_bib24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2019.101137_bib25","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"G1","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.101137_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101137_bib27","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.101137_bib28","doi-asserted-by":"crossref","first-page":"73483","DOI":"10.18632\/oncotarget.19008","article-title":"Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions","volume":"8","author":"Valent","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.beha.2019.101137_bib29","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.101137_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ebiom.2017.11.024","article-title":"Proposed terminology and classification of pre-malignant neoplastic conditions: a consensus proposal","volume":"26","author":"Valent","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.beha.2019.101137_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000489042","article-title":"Diagnostic criteria, separation from MDS and clinical implications","volume":"86","author":"Valent","year":"2019","journal-title":"Pathobiology"},{"issue":"3","key":"10.1016\/j.beha.2019.101137_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030789","article-title":"Clonal hematopoiesis with oncogenic potential (CHOP): separation from CHIP and roads to AML","volume":"20","author":"Valent","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.beha.2019.101137_bib33","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3109\/10428194.2016.1143938","article-title":"Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?","volume":"57","author":"Elb\u00e6k","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2019.101137_bib34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.leukres.2016.05.013","article-title":"Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: a series of 26 cases and literature review","volume":"47","author":"Grignano","year":"2016","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.beha.2019.101137_bib35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc.2017.40","article-title":"Turning the tide in myelodysplastic\/myeloproliferative neoplasms","volume":"17","author":"Deininger","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.beha.2019.101137_bib36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2257.2002.00454.x","article-title":"Not all cases of idiopathic thrombocytopenic purpura (correction of pupura) are what they might first seem","volume":"24","author":"Mainwaring","year":"2002","journal-title":"Clin Lab Haematol"},{"issue":"3","key":"10.1016\/j.beha.2019.101137_bib37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40520-013-0053-6","article-title":"Chronic myelomonocytic leukemia presenting as relapsing thrombotic thrombocytopenic purpura","volume":"25","author":"Cai","year":"2013","journal-title":"Aging Clin Exp Res"},{"issue":"6","key":"10.1016\/j.beha.2019.101137_bib38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/ejh.12393","article-title":"Immune thrombocytopenia in chronic myelomonocytic leukemia","volume":"93","author":"Hadjadj","year":"2014","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2019.101137_bib39","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3324\/haematol.11118","article-title":"A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML","volume":"92","author":"Lacronique-Gazaille","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2019.101137_bib40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/10428194.2010.533801","article-title":"Acute monoblastic\/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells","volume":"52","author":"Kern","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.beha.2019.101137_bib41","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ejh.12477","article-title":"Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response","volume":"95","author":"Shen","year":"2015","journal-title":"Eur J Haematol"},{"issue":"23","key":"10.1016\/j.beha.2019.101137_bib42","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2019.101137_bib43","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood-2017-04-779579","article-title":"Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML","volume":"130","author":"Selimoglu-Buet","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101137_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fonc.2018.00109","article-title":"Evaluation by flow cytometry of mature monocyte subpopulations for the diagnosis and follow-up of chronic myelomonocytic leukemia","volume":"8","author":"Picot","year":"2018","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.beha.2019.101137_bib45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ajcp\/aqy054","article-title":"Clinical utility of classical and nonclassical monocyte percentage in the diagnosis of chronic myelomonocytic leukemia","volume":"150","author":"Hudson","year":"2018","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.beha.2019.101137_bib46","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/cyto.b.21721","article-title":"Application of immunophenotypic analysis in distinguishing chronic myelomonocytic leukemia from reactive monocytosis","volume":"94","author":"Feng","year":"2018","journal-title":"Cytom B Clin Cytom"},{"key":"10.1016\/j.beha.2019.101137_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2018.08.015","article-title":"Emerging utility of flow cytometry in the diagnosis of chronic myelomonocytic leukemia","volume":"73","author":"Hudson","year":"2018","journal-title":"Leuk Res"},{"issue":"13","key":"10.1016\/j.beha.2019.101137_bib48","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2016-12-753210","article-title":"Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis","volume":"129","author":"Talati","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2019.101137_bib49","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1038\/bcj.2017.66","article-title":"Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis","volume":"7","author":"Patnaik","year":"2017","journal-title":"Blood Canc J"},{"issue":"9","key":"10.1016\/j.beha.2019.101137_bib50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-019-0231-7","article-title":"Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia","volume":"9","author":"Pophali","year":"2019","journal-title":"Blood Canc J"},{"key":"10.1016\/j.beha.2019.101137_bib51","article-title":"Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime?","author":"Solary","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1016\/j.beha.2019.101137_bib52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.seminoncol.2011.11.008","article-title":"Integration of next-generation sequencing into clinical practice: are we there yet?","volume":"39","author":"Kohlmann","year":"2012","journal-title":"Semin Oncol"},{"issue":"19","key":"10.1016\/j.beha.2019.101137_bib53","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2019.101137_bib54","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25104","article-title":"Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.beha.2019.101137_bib55","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2019.101137_bib56","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2019.101137_bib57","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/leu.2017.164","article-title":"Genomic determinants of chronic myelomonocytic leukemia","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2019.101137_bib58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.beha.2019.101137_bib59","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.humpath.2014.08.014","article-title":"The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia","volume":"45","author":"Federmann","year":"2014","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.beha.2019.101137_bib60","first-page":"172","article-title":"The clinical management of chronic myelomonocytic leukemia","volume":"12","author":"Padron","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"10.1016\/j.beha.2019.101137_bib61","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.leukres.2014.01.006","article-title":"Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival","volume":"38","author":"Pleyer","year":"2014","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.beha.2019.101137_bib62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MOH.0000000000000112","article-title":"Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies","volume":"22","author":"Padron","year":"2015","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1016\/j.beha.2019.101137_bib63","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2017-04-736421","article-title":"How I treat chronic myelomonocytic leukemia","volume":"130","author":"Solary","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2019.101137_bib64","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11899-017-0408-8","article-title":"Therapy for chronic myelomonocytic leukemia in a new era","volume":"12","author":"Moyo","year":"2017","journal-title":"Curr Hematol Malignancy Rep"},{"issue":"12","key":"10.1016\/j.beha.2019.101137_bib65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11864-018-0581-6","article-title":"Current management and recent advances in the treatment of chronic myelomonocytic leukemia","volume":"19","author":"Hunter","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.beha.2019.101137_bib66","first-page":"1","article-title":"Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system","volume":"14","author":"Diamantopoulos","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.beha.2019.101137_bib67","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"HemaSphere"},{"issue":"6","key":"10.1016\/j.beha.2019.101137_bib68","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1016\/j.beha.2019.101137_bib69","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2019.101137_bib70","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3324\/haematol.2013.084020","article-title":"Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups","volume":"98","author":"Onida","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.beha.2019.101137_bib71","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2019.101137_bib72","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/138945007779940124","article-title":"Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders","volume":"8","author":"Reiter","year":"2007","journal-title":"Curr Drug Targets"},{"issue":"11","key":"10.1016\/j.beha.2019.101137_bib73","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajh.24880","article-title":"World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gotlib","year":"2017","journal-title":"Am J Hematol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619301318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619301318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:53Z","timestamp":1761498353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692619301318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1521692619301318"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.101137","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.101137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101137"}}